GSK Pharma's Q1 FY27 saw strong results: Sales at ₹924 Cr (+15% YoY), EBITDA +17%, PAT ₹253 Cr (+24%). Margin expansion was notable.

Innovation now drives 7% of revenue, with Shingrix growing 65% and oncology launches impacting 250-300 patients quarterly.

Key upcoming launches like Blenrep (multiple myeloma) in Q2/Q3 and Bepirovirsen (hepatitis B functional cure) within three quarters.

Management targets ₹8,000 Cr top-line in 4-5 years, emphasizing pipeline acceleration and portfolio transformation towards specialty assets for sustained growth.

Opex was front-loaded this quarter due to strategic investments.